Liu Xiling, Kang Xichun, Kang Haiyan, Yan Huimin
School of Public Health, Hebei Medical University, Shijiazhuang, 050017, China.
Hebei Key Laboratory of Immune Mechanism of Major Infectious Diseases and New Technology of Diagnosis and Treatment, The Fifth Hospital of Shijiazhuang, Shijiazhuang, 050021, China.
Cell Commun Signal. 2025 Mar 27;23(1):155. doi: 10.1186/s12964-025-02170-7.
Hepatocellular carcinoma (HCC) is a prevalent malignancy with a significant global burden. Despite substantial advancements in HCC treatment in recent years, therapeutic efficacy remains constrained by immune evasion mechanisms within the tumor microenvironment (TME). Myeloid-derived suppressor cells (MDSCs), as critical immunosuppressive elements of the TME, have garnered increasing attention for their role in tumor progression. Recent studies emphasize their central involvement in promoting immune evasion, tolerance, and immunosuppression in HCC. This review examines the contributions of MDSCs to HCC pathogenesis, elucidates their underlying mechanisms, and discusses ongoing clinical trials, emphasizing their potential as therapeutic targets for improving clinical outcomes.
肝细胞癌（HCC）是一种常见的恶性肿瘤，在全球造成重大负担。尽管近年来HCC治疗取得了重大进展，但治疗效果仍受到肿瘤微环境（TME）中免疫逃逸机制的限制。髓源性抑制细胞（MDSCs）作为TME的关键免疫抑制成分，因其在肿瘤进展中的作用而受到越来越多的关注。最近的研究强调了它们在促进HCC免疫逃逸、耐受和免疫抑制中的核心作用。本综述探讨了MDSCs对HCC发病机制的贡献，阐明了其潜在机制，并讨论了正在进行的临床试验，强调了它们作为改善临床结果的治疗靶点的潜力。
